Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 296

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 296
---
 Preferred Stock Financing From August 2023 to January 2024, we issued and sold an aggregate of 50 million shares of our Series C preferred stock at a purchase price of $1.50 per share for aggregate gross proceeds of $75.0 million. In addition, in August 2023, we issued an aggregate of 23,820,346 shares of our Series C preferred stock in exchange of the principal amount of all outstanding convertible notes at a conversion price of $1.50 per share. However, prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and have received their shares in prior offerings at prices lower than the price offered to the public in this offering. The table below sets forth the number of shares of our Series C preferred stock purchased by our related parties. See the section titled “Principal Stockholders” for additional information.

| Name Of Stockholder                    |     | Shares of   
 Series C    
 Convertible 
 Preferred   
 Stock (#)   |            |     | Total     
 Purchase  
 Price ($) |            |
| Deep Track Biotechnology Master Fund,  
 Ltd.(1)                                |     |             | 16,666,667 |     |           | 25,000,000 |
| Entities affiliated with Vida          
 Ventures(2)                            |     |             | 13,333,333 |     |           | 19,999,999 |
| Entities affiliated with Pontifax(3)   |     |             | 10,000,000 |     |           | 15,000,000 |
| Entities affiliated with TCG Crossover 
 Fund(4)                                |     |             | 10,000,000 |     |           | 15,000,000 |

| (1) | Rebecca Luse, a member of our board of directors, is a Principal of Deep Track Capital. |

| (2) | Rajul Jain, M.D., a member of our board of directors, is a Managing Director of Vida Ventures. |

| (3) | Ran Nussbaum, a member of our board of directors, is a Managing Partner and the 
 Co-Founder of Pontifax.                                                         |

| (4) | Chen Yu, M.D., a member of our board of directors, is a Founder and Managing Partner of TCG Crossover Fund. |

Royalty Agreements In July 2016, we entered into several Original Royalty Agreements with certain of our existing investors